Clinical Trials Sponsored by Kowa Pharmaceuticals America, Inc.

Total 149 results

Kowa Research Institute, Inc.
Eli Lilly and Company; Kowa Pharmaceuticals America, Inc.

Completed

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

Dyslipidemia

United States
University of Kansas Medical Center
Eli Lilly and Company; Kowa Pharmaceuticals America, Inc.

Completed

A Study Comparing CoQ10 Levels While Taking 3 Different Statins (SPARQ)

Hypercholesterolemia

United States
Massachusetts General Hospital
Takeda Pharmaceuticals North America, Inc.; American College of Gastroenterology

Recruiting

Identification/Characterization of Changes in Microscopic Colitis

Colitis, Microscopic

United States
AstraZeneca
Takeda Pharmaceuticals North America, Inc.

Terminated

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

Obesity

United States
Takeda
Takeda Pharmaceuticals North America, Inc.

Completed

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

Diabetes Mellitus
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

Bipolar Disorder

United States, South Africa, Brazil, Russian Federation, France, Czechia, Croatia, India, Bulgaria
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Behavioral Symptoms | Autistic Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Dementia | Alzheimer's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Switch Study of BMS-337039 in Schizophrenic Out-patients

Schizophrenia

Belgium, Spain, Italy, Austria, Germany, France, Czech Republic, United Kingdom, Greece, Hungary
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients

Schizophrenia

Turkey, Austria, Germany, South Africa, Sweden, Finland, Czech Republic, Poland, France, Hungary, United Kingdom, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Acute Bipolar Mania

Bipolar Disorder

United States, Mexico, Peru, South Africa, Russian Federation, Croatia, Bulgaria
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

Bipolar Disorder

United States, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Acute Mania

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Schizophrenia Trial of Aripiprazole

Schizophrenia

Austria, United Kingdom, France, Spain, Sweden, Czech Republic, Denmark, Finland, Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Patients With Bipolar I Disorder

Bipolar Disorder

France, Portugal, Spain, Italy, Germany, South Africa, United Kingdom, United States, Russian Federation, Poland, Czech Republic, Hungary, Netherlands, Estonia, Australia, Bulgaria, Switzerland
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Withdrawn

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar Disorder

United States, India
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Schizophrenia

France, South Africa, Canada, Russian Federation, Poland, Czech Republic, Hungary, Croatia, Netherlands, Romania, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type

Dementia, Alzheimer Type
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Bipolar Disorder Mania

Italy, Poland, Russian Federation, Turkey, South Africa, Austria, Hungary, France, Spain, Czech Republic, Germany, Greece, Romania
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Broad Effectiveness: Study With Aripiprazole

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Study of Aripiprazole in Subjects With Alcoholism

Alcoholism

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder | Psychotic Disorder | Body Weight Change

United States, Brazil, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Parkinson's Disease | Psychoses

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Effect on Cognitive Function of a Treatment With Aripiprazole

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Schizophrenia

Belgium, France, Netherlands, Portugal, Spain
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

Schizophrenia and Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Aripiprazole Oral Acceptability Trial

Schizophrenia

United States
Massachusetts General Hospital
Alkermes, Inc.; Otsuka America Pharmaceutical; Eisai Inc.; Janssen Pharmaceuticals and other collaborators

Recruiting

National Pregnancy Registry for Atypical Antipsychotics

Depression | Schizophrenia | Schizoaffective Disorder | Bipolar Disorder | Use of Atypical Antipsychotics During Pregnancy

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Withdrawn

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Opioid-Induced Constipation

Canada, United States, France, Spain
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Opioid-Induced Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

Constipation

Korea, Republic of, Taiwan
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain

Constipation
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Ileus

United States, South Africa, Canada, Hungary, Poland, Australia, Belgium, Germany, Italy, Korea, Republic of, Netherlands
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, United Kingdom, Brazil, Spain, Sweden
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Portugal, United Kingdom
Merz North America, Inc.
Merz Pharmaceuticals GmbH

Completed

Safety, Effectiveness and Participant Satisfaction Study of a Dermal Filler (of RADIESSE® (+) Lidocaine) in the Treatment of Ageing Signs in the Face (RaLido)

Signs of Facial Aging With Volume Loss in the Upper Cheeks, Nasolabial Folds and Marionette Lines

Germany
Merz Pharmaceuticals GmbH
Merz North America, Inc.

Completed

Blepharospasm Patient Survey for Patients With Blepharospasm

Blepharospasm

United States
Augusta University
Takeda Pharmaceuticals North America, Inc.

Completed

Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.

Chronic Constipation, Methanogenesis

United States
Boston University
Takeda Pharmaceuticals North America, Inc.

Completed

Use of Expressive Writing in Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome
Cascade Pharmaceuticals, Inc
Laboratory Corporation of America

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Nonalcoholic Steatohepatitis (NASH)

United States

Clinical Trials Sponsored by Kowa Pharmaceuticals America, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations